Astellas is committed to providing timely and accurate information about our business, science and products. This section offers global resources for investors, journalists and media professionals. News and resources from our local affiliates can be viewed in the Local news section. If you are not an investor or journalist, click here.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Tokyo, Feb. 2, 2015—Astellas Pharma Inc. (Tokyo: 4503, “Astellas”) announced today that the company will now make trial data available through www.clinicalstudydatarequest.com, an...
Read more about ASTELLAS BROADENS COMMITMENT TO CLINICAL TRIAL DATA TRANSPARENCY
Hershey, PA & Rockville, MD and Tokyo, Japan. January 30, 2015 – Immunomic Therapeutics, Inc. (“Immunomic Therapeutics”), a company developing next generation vaccines based on the LAMP-vax...
SAN FRANCISCO, CA and TOKYO, JAPAN – January 22, 2015 – Medivation, Inc. (NASDAQ: MDVN) and Astellas Pharma Inc. (TSE: 4503) today announced topline results from the Phase 2 TERRAIN trial...
NORTHBROOK, Ill., January 22, 2015, – Astellas today announced that the U.S. Food and Drug Administration’s (FDA) Anti-infective Drugs Advisory Committee voted unanimously to recommend...
South San Francisco, CA, and Tokyo, December 23, 2014 – Cytokinetics, Incorporated (NASDAQ:CYTK) and Astellas Pharma Inc. (Tokyo Stock Exchange: 4503, "Astellas") announced today an amendment to...
Follow us
